Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical–stage natural psychedelic drug development company, today announced interim safety reporting from its Phase I clinical trial in partnership with the University of California, San Francisco (UCSF)’s Translational Psychedelic Research Program (TrPR). Four healthy subjects have been dosed with Filament’s botanical psilocybin drug candidate, PEX010, as well as the Company’s botanical psilocin drug candidates, PEX020 and PEX030.

“These are the first reported clinical trial results regarding a naturally sourced psychedelic drug. We are pleased with our progress thus far. Because the drug candidates have been well-tolerated, the study will continue as planned.”

Dr. Joshua Woolley, MD/Ph.D., director of TrPR and the study’s Principal Investigator

Fifteen doses of Filament’s drug candidates have been given, and all were reported to be well tolerated with no serious or unexpected adverse events. This is the first FDA-approved clinical trial of a naturally-derived psychedelic drug candidate, as well as the first time that psilocin has been directly administered in a clinical trial.

“We’re proud to continue our relationship with UCSF and to have such promising early results,” said Benjamin Lightburn, Chief Executive Officer and Co-Founder of Filament Health. “This industry-first trial is a testament to Filament’s innovative drug development and operational capabilities.”

About Filament Health

Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.